CrushSCI.com
Journal Selection & Manuscript Polishing Services
Signal Transduction and Targeted Therapy journal cover Medicine
Back to journal directory

Review Cycle Records

Signal Transduction and Targeted Therapy

Springer SCIE OA
2026 Emerging Zone 12025 CAS Zone 1 TOP2025 JCR Q1
213.9Average days
257Median days
8Fastest days
385Longest days
4282025 publications

Paper Review Records

All Paper Review Records

15 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.

41 days

EBV-driven Gate–License–Amplify circuit in multiple sclerosis pathogenesis

AuthorsYuxin Li; Xiaofei Shi; Yuxiao Zhang; Mu-Sheng Zeng; Qian Zhong; Wanli Liu

Affiliations1. School of Management & Engineering, Nanjing University, Nanjing, China; 2. Jiangsu Key Laboratory of Digital Finance, Suzhou, China; 3. State Key Laboratory of Membrane Biology, School of Life Sciences, Tsinghua-Peking Center for Life Sciences, Institute for Immunology, Ministry of Education Key Laboratory of Protein Sciences, Tsinghua University, Beijing, China; 4. Department of Rheumatology and Immunology, The First Affiliated Hospital, College of Clinical Medicine, Henan University of Science and Technology, Luoyang, China; 5. State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Department of Experimental Research, Sun Yat-sen University Cancer Center, Sun Yat-sen University, Guangzhou, China

Source PDF DOI Publisher page
257 days

Oral nonpeptide GLP-1 receptor agonist VCT220 for obesity treatment: a randomized, double-blind, phase II trial

AuthorsLinong Ji; Leili Gao; Ben Li; Mei Liu; Xianghua Zhang; Chao Meng

Affiliations1. Department of Endocrinology, Peking University People’s Hospital, Beijing, China; 2. Chengdu Vincentage Pharma Co. Ltd., Chengdu, China; 3. Department of General Medicine, Yueyang Central Hospital, Yueyang, China; 4. Department of General Medicine, Central Hospital Affiliated to Shandong First Medical University, Jinan, China

Source PDF DOI Publisher page
302 days

Mefatinib versus gefitinib as a first-line treatment for EGFR-mutated non-small cell lung cancer: a randomized, double-blind, multicenter phase III study

AuthorsJia Yu; Anwen Xiong; Qiming Wang; Jianhua Chen; Hongrui Niu; Chengzhi Zhou; Panwen Tian; Wu Zhuang; Jie Li; Jing Wang; Junguo Lu; Kangsheng Gu; Jinsheng Shi; Jun Guo; Yonghui Di; Dongqing Lv; Debin Sun; Liming Cao; Zhixiong Yang; Jingxun Wu; Liyun Miao; Yueyin Pan; Chong Li; Xiaohong Wu; Jie Yin; Xiang Wang; Meili Sun; Miao He; Shundong Cang; Haohui Fang; Ping Chen; Min Zhang; Xinmei Yang; Hui Zhao; Jian Feng; Xuezhen Ma; Sheng Hu; Jian Lu; Xin Zhao; Zhixiang Zhuang; Yilan Sun; Xu Sun; Bing Yu; Chaonan Zhu; Jianghua Chen; June Xu; Kai Wang; Caicun Zhou

Affiliations1. Department of Medical Oncology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China; 2. Department of Respiratory Medicine, Henan Cancer Hospital, Zhengzhou, China; 3. Department of Medical Oncology, Hunan Cancer Hospital, Changsha, China; 4. Department of Oncology, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, China; 5. State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Department of Pulmonary and Critical Care Medicine, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China; 6. Department of Respiratory and Critical Care Medicine, West China School of Medicine/West China Hospital of Sichuan University, Chengdu, China; 7. Department of Thoracic Oncology, Fujian Cancer Hospital & Fujian Medical University Cancer Hospital, Fuzhou, China; 8. Department of Respiratory Medicine, First Affiliated Hospital of Gannan Medical University, Ganzhou, China; 9. Department of Respiratory Medicine, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China; 10. Department of Respiratory Medicine, Nantong Tumor Hospital, Nantong, China; 11. Medical Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China; 12. Department of Oncology, Cangzhou People’s Hospital, Cangzhou, China; 13. Department of Medical Oncology, Xingtai People’s Hospital, Hebei, China; 14. Department of Thoracic Surgery, Xingtai People’s Hospital, Xingtai, China; 15. Department of Respiratory Medicine, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Taizhou, China; 16. Respiratory Department, Lishui Central Hospital, Lishui, China; 17. Department of Respiratory Medicine, Xiangya Hospital Central South University, Changsha, China; 18. Department of Oncology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China; 19. Department of Medical Oncology, The First Affiliated Hospital of Xiamen University, Xiamen, China; 20. Department of Respiratory and Critical Care Medicine, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China; 21. Division of Life Sciences and Medicine, Department of Medical Oncology, The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, China; 22. Department of Respiration, First People’s Hospital of Changzhou, Third Affiliated Hospital of Soochow University, Changzhou, China; 23. Department of Medical Oncology, The Affiliated Hospital of Jiangnan University (The Fourth People’s Hospital in Wuxi City), Wuxi, China; 24. Department of Respiratory and Critical Care Medicine, General Hospital of the Eastern Theatre of the Chinese People’s Liberation Army, Nanjing, China; 25. Department of Oncology, Xuzhou Central Hospital, Xuzhou, China; 26. Department of Oncology, Jinan Central Hospital, Jinan, China; 27. Oncology Department, Deyang People’s Hospital, Deyang, China; 28. Department of Oncology, Henan Provincial People’s Hospital, Zhengzhou, China; 29. Department of Respiratory Medicine, Anhui Chest Hospital, Hefei, China; 30. Department of Oncology, Yancheng NO.1 People’s Hospital, Yancheng, China; 31. Department of Pulmonary and Critical Care Medicine, Ganzhou People’s Hospital, Ganzhou, China; 32. Department of Radiation Oncology, The First Hospital of Jiaxing, Jiaxing, China; 33. Department of Respiratory Medicine, Second Affiliated Hospital of Anhui Medical University, Hefei, China; 34. Department of Respiratory and Critical Care Medicine, Affiliated Hospital and Medical School of Nantong University, Nantong, China; 35. Department of Oncology, Affiliated Qingdao Central Hospital of Qingdao University, Qingdao Cancer Hospital, Qingdao, China; 36. Department of Thoracic Oncology, Hubei Cancer Hospital, Wuhan, China; 37. Department of Oncology, The Affiliated Hospital of Qingdao University, Qingdao, China; 38. Department of Respiratory and Critical Care Medicine, Jiangsu Province Hospital and The First Affiliated Hospital with Nanjing Medical University, Nanjing, China; 39. Department of Oncology, The Second Affiliated Hospital of Soochow University, Suzhou, China; 40. Department of Pulmonary and Critical Care Medicine, Zhejiang Provincial People’s Hospital, Hangzhou, China; 41. Hangzhou Zhongmei Huadong Pharmaceutical Company, Hangzhou, China; 42. Department of Respiratory Medicine, The Second Affiliated Hospital of Medical College of Zhejiang University, Hangzhou, China; 43. Department of Respiratory and Critical Care Medicine, The Fourth Affiliated Hospital of Zhejiang University School of Medicine, Yiwu, China; 44. Department of Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China

Source PDF DOI Publisher page
365 days

Translational insights and clinical challenges of targeting cancer stem cells

AuthorsMehreen Ahmed; Amr Al-Haidari; Shruti Agarwal; Jianmin Sun; Emma U. Hammarlund; Lars Rönnstrand; Kenneth J. Pienta; Özge Tatli; Julhash U. Kazi

Affiliations1. Division of Translational Cancer Research, Department of Laboratory Medicine, Lund University, Lund, Sweden; 2. Lund Stem Cell Center, Department of Laboratory Medicine, Lund University, Lund, Sweden; 3. Lund University Cancer Centre (LUCC), Lund University, Lund, Sweden; 4. Department of Surgery and Cancer, Imperial College London, London, UK; 5. Department of Urology, University of Rochester Medical Center, Rochester, USA; 6. Institute of Medical Genetics and Genomics, Sir Ganga Ram Hospital, New Delhi, India; 7. School of Basic Medical Sciences, Ningxia Medical University, Yinchuan, China; 8. Tissue Development and Evolution (TiDE), Department of Experimental Medical Science, Lund University, Lund, Sweden; 9. Division of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden; 10. The Cancer Ecology Center, Brady Urological Institute, Johns Hopkins School of Medicine, Baltimore, USA; 11. Department of Molecular Biology and Genetics, Faculty of Engineering and Natural Sciences, Istanbul Medeniyet University, Istanbul, Türkiye

Source PDF DOI Publisher page
276 days

From probe to prodrug: immunoproteasome activity as a trigger for disease-selective therapeutics

AuthorsCody A. Loy; Yijun Gu; Samuel C. Kim; Mariam V. Mohagheghi; Noah B. Trask; Marina Suarez-Pizarro; Lisa E. Wagar; Claudia A. Benavente; Darci J. Trader

Affiliations1. Department of Pharmaceutical Sciences, University of California, Irvine, USA; 2. Robert A. Mah Molecular Innovation Center, University of California, Irvine, USA; 3. Department of Physiology and Biophysics, University of California, Irvine, USA; 4. Adeline Yen Mah Vaccine Center, University of California, Irvine, USA; 5. Institute for Immunology, University of California, Irvine, USA; 6. Center for Virus Research, University of California, Irvine, USA; 7. Department of Developmental and Cell Biology, University of California, Irvine, USA; 8. Chao Family Comprehensive Cancer Center, University of California, Irvine, USA; 9. Deparment of Chemistry, University of California, Irvine, USA

Source PDF DOI Publisher page

Expert Matching · Case Demo

Turn Your Submission Goalsinto a Verifiable Journal Plan

Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.

CrushSCI online

Client

I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?

CrushSCI

Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.

Suggested title
Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment

SampleLatest 5 valid paper samples from 2026

Average review96.4 days

Median77 days

Contact CrushSCI

Contact CrushSCI

Leave your contact details so we can discuss your manuscript, editing needs, and submission plan.

Selected service: Paper Editing Service

Or leave your contact details

WhatsApp, Telegram, WeChat, and email are all optional, but at least one is required. Once received, we will contact you as soon as possible.